Avacopan (Tavneos®). HTA ID: 22009

Assessment Status NCPE Assessment Process Complete
HTA ID 22009
Drug Avacopan
Brand Tavneos®
Indication In combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis or microscopic  polyangiitis.  
Assessment Process
Rapid review commissioned 14/02/2022
Rapid review completed 08/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avacopan (Tavneos®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/04/2022
Pre-submission consultation with Applicant 21/06/2022
Full submission received from Applicant 19/10/2022
Preliminary review sent to Applicant 24/02/2023
NCPE assessment re-commenced 28/04/2023
Factual accuracy sent to Applicant 03/07/2023
NCPE assessment re-commenced 11/07/2023
NCPE assessment completed 20/07/2023
NCPE assessment outcome The NCPE recommends that avacopan not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.